Aaron N. Snead
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aaron N. Snead has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Albert Parker
Vividion Therapeutics, San Diego, California
24 shared publications - Benjamin D. Horning
Vividion Therapeutics, San Diego, California
24 shared publications - Brent Kuenzi
Division of Genetics, Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA
24 shared publications - Christie L. Eissler
Vividion Therapeutics, San Diego, California
24 shared publications - David S. Weinstein
Vividion Therapeutics, San Diego, California
24 shared publications - Dhaval P. Bhatt
Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri
24 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
Shows chemo-proteomic analysis of VVD-065 selectivity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
Shows chemo-proteomic analysis of VVD-065 selectivity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
Shows cysteine-directed selectivity analysis of VVD-065 and related compounds
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
Shows cysteine-directed selectivity analysis of VVD-065 and related compounds
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
Shows VVD-065 enhances NRF2 ubiquitination by increasing the KEAP1- CUL3 protein-protein interaction
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
Shows VVD-065 enhances NRF2 ubiquitination by increasing the KEAP1- CUL3 protein-protein interaction
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Method 1 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
Shows synthesis routes of compounds
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Method 1 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
Shows synthesis routes of compounds
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 14 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
Shows additional analysis of the tumor growth inhibition study in the KLN205 syngeneic model, and evaluation of the tolerability of VVD-065 in combination with chemotherapy in patient-derived xenograft models
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 14 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
Shows additional analysis of the tumor growth inhibition study in the KLN205 syngeneic model, and evaluation of the tolerability of VVD-065 in combination with chemotherapy in patient-derived xenograft models
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Method 2 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Method 2 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 12 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
Shows TGI effects of VVD-065 and NRF2 genetic ablation in a variety of cell line derived xenograft models
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 12 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
Shows TGI effects of VVD-065 and NRF2 genetic ablation in a variety of cell line derived xenograft models
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
Shows further evaluation of VVD-065, including assessment of the acetamide analog's lack of activity, determination of VVD-065 reaction kinetics, and additional structural analysis of the compound
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
Shows further evaluation of VVD-065, including assessment of the acetamide analog's lack of activity, determination of VVD-065 reaction kinetics, and additional structural analysis of the compound
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
Shows distribution of physicochemical properties for the covalent fragment library and initial chemoproteomic screening results
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
Shows distribution of physicochemical properties for the covalent fragment library and initial chemoproteomic screening results